ducovest

XVIPF:OTO-Xvivo Perfusion Ab Ord (USD)

COMMON STOCK | Medical Devices | OTC Pink

Last Closing

USD 34.01

Change

0.00 (0.00)%

Market Cap

USD 0.22B

Volume

N/A

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Xvivo Perfusion AB is a medical technology company focused on developing optimized solutions for organ, tissue and cell preservation in connection with transplantation.

Company Website : http://www.xvivoperfusion.com

Currency: USD

Country : USA

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-05-03 )

Largest Industry Peers for Medical Devices

Symbol Name Price(Change) Market Cap
SEMHF Siemens Healthineers AG

N/A

 USD 67.69B
SMMNY Siemens Healthineers AG ADR

-0.41 (-1.41%)

 USD 67.09B
RYLPF Koninklijke Philips N.V

N/A

 USD 26.13B
CHEOY CochLear Ltd ADR

-1.53 (-1.42%)

 USD 13.97B
CHEOF Cochlear Limited

N/A

 USD 13.46B
SNNUF Smith & Nephew plc

N/A

 USD 11.57B
WILYY Demant A/S ADR

N/A

 USD 10.38B
WILLF Demant A/S

N/A

 USD 10.35B
AMBFF Ambu A/S

N/A

 USD 5.73B
GNGBF Getinge AB

N/A

 USD 5.38B

ETFs Containing XVIPF

RUBY-U:CA RBC U.S. Banks Yield Inde.. 7.38 % 0.00 %

-1.14 (-7.56%)

 N/A
HUBL-U:CA Harvest US Bank Leaders I.. 6.52 % 0.00 %

N/A

 N/A
IUS2:F iShares S&P U.S. Banks UC.. 3.81 % 0.00 %

-0.04 (-7.56%)

 USD 0.33B
IUS2:XETRA iShares S&P U.S. Banks UC.. 3.81 % 0.00 %

N/A

 USD 0.33B
FBU:CA 2.78 % 0.84 %

N/A

 N/A
UINC:LSE First Trust US Equity Inc.. 2.72 % 0.00 %

-1.50 (-7.56%)

 USD 0.31B
KRS 2.30 % 0.95 %

N/A

 N/A
KRU 2.30 % 0.95 %

N/A

 N/A
MVIN 2.28 % 0.55 %

N/A

 N/A
DPST Direxion Daily Regional B.. 1.98 % 1.02 %

-2.44 (-7.56%)

 USD 0.55B

Market Performance

  Market Performance vs. Industry/Classification (Medical Devices) Market Performance vs. Exchange (OTC Pink)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 49.17% 87% B+ 88% B+
Dividend Return N/A N/A N/A N/A N/A
Total Return 49.17% 87% B+ 88% B+
Trailing 12 Months  
Capital Gain 49.82% 89% A- 88% B+
Dividend Return N/A N/A N/A N/A N/A
Total Return 49.82% 89% A- 87% B+
Trailing 5 Years  
Capital Gain 136.18% 91% A- 91% A-
Dividend Return N/A N/A N/A N/A N/A
Total Return 136.18% 91% A- 90% A-
Average Annual (5 Year Horizon)  
Capital Gain 31.81% 71% C- 72% C
Dividend Return 31.81% 71% C- 69% C-
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 78.86% 47% F 38% F
Risk Adjusted Return 40.34% 89% A- 78% C+
Market Capitalization 0.22B 81% B- 70% C-

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

What to not like:
Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Negative earnings

The company had negative total earnings in the most recent four quarters.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.